tirofiban has been researched along with Hemorrhagic Thrombocythemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Javed, M; Rahman, MN | 1 |
| Bildirici, U; Celikyurt, U; Ural, E | 1 |
| Demir, M; Fareed, J; Gül, C; Iqbal, O; Kürüm, T; Ozbay, G; Vural, O | 1 |
3 other study(ies) available for tirofiban and Hemorrhagic Thrombocythemia
| Article | Year |
|---|---|
Tirofiban and Rivaroxaban use in the management of right coronary artery thrombus as a primary manifestation of essential thrombocythemia.
Topics: Coronary Vessels; Drug-Eluting Stents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Rivaroxaban; Thrombocythemia, Essential; Thrombosis; Tirofiban | 2022 |
Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female.
Topics: Adult; Age Factors; Antisickling Agents; Aspirin; Clopidogrel; Coronary Angiography; Female; Fibrinolytic Agents; Heparin; Humans; Hydroxyurea; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombocythemia, Essential; Ticlopidine; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2009 |
Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor.
Topics: Female; Humans; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocythemia, Essential; Tirofiban; Treatment Outcome; Tyrosine | 2004 |